# Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

> **NCT05397938** · PHASE2 · UNKNOWN · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 231 (estimated)

## Conditions studied

- Glucocorticoid Induced Osteoporosis

## Interventions

- **DRUG:** JMT103
- **DRUG:** Alendronate sodium
- **DRUG:** JMT103 placebo
- **DRUG:** Alendronate sodium placebo

## Key facts

- **NCT ID:** NCT05397938
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-15
- **Primary completion:** 2022-07-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 231 (ESTIMATED)
- **Last updated:** 2022-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05397938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05397938, "Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05397938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*